Big Pharma - Quo Vadis?

Poor Big Pharma.

The status quo is not and option. But quo vadis?

Uwe Reinhardt, an economics professor at Princeton University, thinks eventually the industry will migrate to smaller organizations producing drugs that affect smaller segments of the population.

There are signs of such changes already: Bristol-Myers cut its research areas to 10 from roughly 35 two years ago, in part to target the use of its research dollars.

But outgoing GSK CEO JP Garnier thinks that more mega mergers are inevitable.

2007 will be interesting for PharmaGossip, to say the least!

This might help with the debate.